← Back to Search
Unknown
MYK-224 for Hypertrophic Cardiomyopathy (MERCUTIO Trial)
Boise, ID
Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
New York Heart Association (NYHA) functional class II or III symptoms at screening.
Men or women diagnosed with oHCM consistent with current American College of Cardiology Foundation/American Heart Association and European Society of Cardiology guidelines, satisfying both of the following criteria:
Must not have
Prior treatment with cardiotoxic agents such as anthracyclines (eg, doxorubicin) or similar
Known infiltrative or storage disorder causing cardiac hypertrophy that mimics HCM, such as Fabry disease, amyloidosis, or Noonan syndrome with left ventricular hypertrophy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
This trial studies the safety, effectiveness, and how the body processes a new drug for Obstructive Hypertrophic Cardiomyopathy (oHCM).
See full description
Who is the study for?
This trial is for men and women with obstructive Hypertrophic Cardiomyopathy (oHCM) who have symptoms, a thickened heart wall, and specific heart function criteria. They must be able to undergo exercise stress testing and not have had certain recent cardiac procedures or treatments.Check my eligibility
What is being tested?
The study tests MYK-224's effects on people with oHCM. It aims to understand how safe it is, how well it works, what the body does to the drug (pharmacokinetics), and how the drug affects the body (pharmacodynamics).See study design
What are the potential side effects?
While specific side effects of MYK-224 are not listed here, common ones in trials may include nausea, headache, dizziness, fatigue or allergic reactions. The trial will monitor participants closely for any adverse effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I experience mild to moderate heart symptoms.
show original
Select...
I have been diagnosed with obstructive hypertrophic cardiomyopathy according to current guidelines.
show original
Select...
My heart screening showed a specific high pressure reading.
show original
Select...
My heart's pumping ability is normal or above normal.
show original
Select...
My heart has thick walls without dilation, not caused by other known diseases.
show original
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been treated with heart-damaging drugs like doxorubicin.
show original
Select...
I have a condition like Fabry disease or amyloidosis that causes thickening of the heart muscle.
show original
Select...
I have had or will have an ICD placed or changed recently.
show original
Select...
I have had heart issues with reduced pumping efficiency.
show original
Select...
I have lung problems that make me short of breath when I exert myself.
show original
Select...
I have irregular heartbeats that come and go, confirmed by an ECG.
show original
Select...
I have a history of sudden cardiac arrest or my ICD activated due to a severe heart rhythm issue in the last 6 months.
show original
Select...
I have a health condition that prevents me from doing exercise stress tests.
show original
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Cohort 2Experimental Treatment1 Intervention
Participants will receive MYK-224 in combination with standard-of-care consisting of either a calcium channel blocker or disopyramide (which is given in combination with either a beta-blocker or calcium channel blocker). Participants who complete Cohort 2 will be eligible for an optional open label extension period
Group II: Cohort 1Experimental Treatment1 Intervention
Participants will receive MYK-224 either as a monotherapy or in combination with standard-of-care consisting of a beta-blocker. Participants who complete Cohort 1 will be eligible for an optional open label extension period
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MYK-224
2023
Completed Phase 1
~90
Find a Location
Closest Location:University of Cincinnati College Of Medicine· Cincinnati, OH· 99 miles
Who is running the clinical trial?
Bristol-Myers SquibbLead Sponsor
2,712 Previous Clinical Trials
4,125,772 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I experience mild to moderate heart symptoms.I have been treated with heart-damaging drugs like doxorubicin.I have had or will have an ICD placed or changed recently.I have had heart issues with reduced pumping efficiency.I have been diagnosed with obstructive hypertrophic cardiomyopathy according to current guidelines.I have a condition like Fabry disease or amyloidosis that causes thickening of the heart muscle.I have lung problems that make me short of breath when I exert myself.I had or plan to have heart surgery or a procedure to improve blood flow within the last 6 months.My heart screening showed a specific high pressure reading.Your heart's peak gradient was measured after exercise and needs to be within a certain range.Your heart can be clearly seen and examined using an ultrasound test.I have irregular heartbeats that come and go, confirmed by an ECG.Your heart's electrical activity, called QT interval, is too long and may be risky for your safety.My doctor says I have moderate to severe narrowing of my aortic valve.My heart's pumping ability is normal or above normal.I have a history of sudden cardiac arrest or my ICD activated due to a severe heart rhythm issue in the last 6 months.I have had heart issues but any procedures were done over 12 weeks ago.My heart has thick walls without dilation, not caused by other known diseases.I have atrial fibrillation not treated with blood thinners for 4 weeks or not controlled in the last 6 months.I have a health condition that prevents me from doing exercise stress tests.I have had fainting spells or rapid heartbeats in the last 6 months.I haven't taken mavacamten or aficamten recently, or it's been over 4 months since I last did.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 1
- Group 2: Cohort 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.